PRESS RELEASE

Nanoform accelerates growth with Director of Project Management appointment

Helsinki, Finland – Nanoform, an innovative drug enabling nanotechnology company, will appoint Miguel Cansado as its Director of Project Management. The newly created role will help Nanoform continue to deliver world-class nanonization services to global partners.

Miguel Cansado will be responsible for defining the project governance model. He will lead a team of talented project managers that support and monitor the progress of each nanonization program. His work will ensure the successful delivery of enhanced API nanoparticles with improved solubility and bioavailability.

Miguel Cansado has over 20 years’ experience in the pharmaceutical industry, applying his background in biotechnology, analytical chemistry and GMP in API and drug product projects. He has substantial expertise in the delivery of large contract manufacturing projects to market through his previous role as Senior Project Manager at Hovione, a well-recognized particle engineering contract development and manufacturing company. Miguel holds a PMP certification from the Project Management Institute and is a member of the PMI Portugal Chapter Board of Directors.

The new appointment coincides with the ongoing construction of Nanoform’s GMP manufacturing plant. The combination of increased capacity and strengthened project and program management organization will enable Nanoform to achieve its aim of doubling the number of drug compounds that reach clinical trials.

Edward Hæggström, CEO of Nanoform said: “Miguel’s exceptional experience in the provision of large-scale manufacturing projects will be integral to achieving our ambitions in the next few years. I am delighted to welcome him to the company as a member of the senior leadership team.”

Miguel Cansado said: “I am very pleased to be joining Nanoform at such an exciting time, as the company matures into a larger organization that still retains exceptional agility. I look forward to helping our partners solve their complex drug development problems to produce outstanding new therapies.”

Notes to the Editor

For further information, images and interview opportunities with Nanoform, please contact:
Pranika Sivakumar at Notch Communications
Pranika.sivakumar@notchcommunications.co.uk
+44 (0) 161 457 7230

About Nanoform

Nanoform Finland Limited is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to reduce clinical attrition and enhance their molecules formulation performance through its best-in-class nanonization™ services. The company’s multi-patented and scalable Controlled Expansion of Supercritical Solutions (CESSᵀᴹ) technology produces nanonized “designed-for-purpose” API particles, as small as 10nm. This enables poorly soluble molecules in the pharmaceutical pipeline to progress into clinical development by increasing their rate of dissolution and improving their bioavailability. Nanoform’s unique nanonization™ technology provides novel opportunities in diverse value enhancing drug delivery applications.

For more information please visit http://www.nanoform.fi/